Administering systemic chemotherapy improves survival for patients with resectable CRCLM

Dr Giacomo Bregni - Francis Crick Institute, London, England
Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )
9 Jul 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK
Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )
14 Jun 2024

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
4 Jun 2024

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )
2 Jun 2024

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France
Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )
24 Apr 2024

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )
9 Feb 2024

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )
8 Feb 2024

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain
Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Jan 2024

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

Dr Thierry André - Sorbonne Université, Paris, France
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )
24 Jan 2024

Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria
Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )
19 Jan 2024

Colorectal cancer risk factors in Nigeria

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria
Colorectal cancer risk factors in Nigeria ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )
19 Jan 2024

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023